全身性硬化症合併間質性肺病治療最新進展

10.6666/ClinMed.202205_89(5).0048

孫易暄；蔡長祐

全身性硬化症（systemic sclerosis, SSc） ； 間質性肺病（interstitial lung disease, ILD）

臨床醫學月刊

89卷5期（2022 / 05 / 27）

293 - 297

繁體中文

全身性硬化症合併間質性肺病往往會對病患日常生活帶來極大的影響。新的藥物如Tocilizumab以及Nintedanib在臨床試驗成功，也對病患帶來新的曙光。

1. Burt, RK,Shah, SJ,Dill, K(2011).Autologous non-myeloablative haemopoietic stemcell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.Lancet,378,498-506.
2. Distler, O,Highland, KB,Gahlemann, M(2019).Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.New Engl J Med,380,2518-2528.
3. Goldin, J,Elashoff, R,Kim, HJ(2009).Treatment of Scleroderma-Interstitial Lung Disease With Cyclophosphamide Is Associated With Less Progressive Fibrosis on Serial Thoracic HighResolution CT Scan Than Placebo Findings From the Scleroderma Lung Study.Chest,136,1333-1340.
4. Highland, KB,Distler, O,Kuwana, M(2021).Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.Lancet Respir Medicine,9,96-106.
5. Hoffmann-Vold, A-M,Allanore, Y,Alves, M(2021).Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.Ann Rheum Dis,80,219-227.
6. Hoyles, RK,Ellis, RW,Wellsbury, J(2006).A multicenter, prospective, randomized, doubleblind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.Arthritis Rheumatism,54,3962-3670.
7. Khanna, D,Lin, CJF,Furst, DE(2020).Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Respir Medicine,8,963-974.
8. Kowal-Bielecka, O,Fransen, J,Avouac, J(2017).Update of EULAR recommendations for the treatment of systemic sclerosis.Ann Rheum Dis,76,1327-1339.
9. Roth, MD,Tseng, C-H,Clements, PJ(2011).Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease.Arthritis Rheumatism,63,2797-2808.
10. Sircar, G,Goswami, RP,Sircar, D(2018).Intravenous cyclophosphamide vs. rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.Rheumatology,57,2106-2113.
11. Sullivan, KM,Goldmuntz, EA,Keyes-Elstein, L(2018).Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.New Engl J Medicine,378,35-47.
12. Tashkin, DP,Elashoff, R,Clements, PJ(2006).Cyclophosphamide versus Placebo in Scleroderma Lung Disease.New Engl J Medicine,354,2655-2666.
13. Tashkin, DP,Roth, MD,Clements, PJ(2016).Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.Lancet Respir Medicine,4,708-719.
14. van,, Laar, JM,Farge, D,Sont, JK(2014).Autologous Hematopoietic Stem Cell Transplantation vs. Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis: A Randomized Clinical Trial.Jama,311,2490-2498.